XIAP and melanoma: Secondly, and of high importance, is that there was no reduced effect of ILP when comparing the two eras, which was true also for patients that previously had received and failed immunotherapy, showing that ILP is still a valid and important treatment option for patients with melanoma in-transit metastasis.